Microbix Biosystems Inc T.MBX

The Numbers

[ECSINVESTOR]

So I look at the company as one transitioning from a speculative one (now that Plexxus deal is signed) to one where analysts start looking more closely at the bottom line? (not that they didn't before...) Below is a copy of part of the press release from Q1. I guess I' m wondering how this deal will affect future earnings. $4.25M for Q3 and Q4 is around $2M/quarter, with the potential to increase/decrease depending on conditions.

So this deal will not double revenue but will definitely give it a large boost. Any commentary on share appreciation from those more savvy than me. I am hoping for better Q2 numbers released in a couple of weeks,which will add fuel to the fire. 

I guess I am asking - what is the compnay worth now (my typical response is - whatever people are willing to pay for it!). Is McWhirter close in his "guess" of $0.90, or is there more upside?

Q1 revenue was $3,157,659, a 54% increase from Q1 2020 revenue of $2,046,348. Included were antigen product revenues of $2,137,829 (Q1 2020 - $1,946,459), a recovery of 9.8%. QAPs revenues were $962,421, an increase of 3,585% from Q1 2020 sales of $26,114, a prior year quarter that contained no REDx™ (IVD) and few PROCEEDx™ (RUO) branded QAPs sales. Finally, royalties were $57,409 (Q1 2020 - $73,775). Q1 sales were most influenced by the broadening diagnostics industry uptake of Microbix’s COVID-19 related QAPs, especially REDx™FLOQ® and PROCEEDx™FLOQ®, followed by the start of a broad-based recovery in antigen sales.

[RazeKreations]

I believe that 90 cents is being very conservative. Robert McWhirter got burnt several times with Kinlytic that is purely speculative that is still waiting for an investor and has not gone anywhere for over a decade. Microbix has reinvented itself with Qaps and Antigens and has built huge gains in distribution of its products over the past year or so as well as having their own label that gains

[Mbxwatcher]

Very happy that we have some real traction on VTM. Taking Q1 numbers is this a stretch? Antigens + 10% to 2,250 VTM 100kX 4.5 ea = 450K Qaps + 25 % to = 1.203 Royalties = 60 Total = 3.9 to 4.0 m An overall increase of 25%  with bigger numbers coming in each category for Q3. I think this is reasonable,   He said yesterday that they sold some more VTM in Q2 than just the initial

[Pandemic2021]

It should certainly move the needle. At that point, 0.90$ should be easily attainable.